ACT Capital is pleased to offer for acquisition a highly profitable, very high growth, medical technology company. The Company’s core business is advancing the art of aesthetic and regenerative injectables. It designs, patents, and manufactures proprietary medical products for the harvesting, processing, and deployment of FDA 361 and FDA 510(k) compliant autologous soft tissue. Over 300 doctors are using the products in the fields of aesthetic and cosmetic surgery applications, regenerative medicine including orthopedic surgery, pain management, and anti-aging procedures.

The Company has experienced rapid growth – 2020 saw a record revenue, with growth of over 30%, and profits, which were up 100%. 2021 continued this upward trajectory, with more that 100% revenue growth and EBITDA tripling. 2022 is on track for another year of more than 50% revenue and EBITDA growth, as well.